Subsequently, studies have shown that silibinin reduces liver fibrosis in nonalcoholic fatty liver disease patients and decreases ALT and AST levels in mice using sibilin capsules. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.